Keiya Uriu1, Paúl Cárdenas2, Erika Muñoz2, Veronica Barragan2, Yusuke Kosugi1, Kotaro Shirakawa3, Akifumi Takaori-Kondo3, Kei Sato1,4. 1. Division of Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. 2. Institute of Microbiology, Universidad San Francisco de Quito, Quito, Ecuador. 3. Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. 4. CREST, Japan Science and Technology Agency, Saitama, Japan.
Abstract
BACKGROUND: We have recently revealed that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Mu variant shows a pronounced resistance to antibodies elicited by natural SARS-CoV-2 infection and vaccination. METHODS: However, it remains unclear which mutations determine the resistance of SARS-CoV-2 Mu to antiviral sera. In addition, it is unclear how SARS-CoV-2 Mu infection induces antiviral immunity. RESULTS: In this study, we reveal that the 2 mutations in the SARS-CoV-2 Mu spike protein, YY144-145TSN and E484K, are responsible for the resistance to coronavirus disease 2019 convalescent sera during early 2020 and vaccine sera. CONCLUSIONS: It is notable that the convalescent sera of SARS-CoV-2 Mu-infected individuals are broadly antiviral against Mu as well as other SARS-CoV-2 variants of concern and interest.
BACKGROUND: We have recently revealed that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Mu variant shows a pronounced resistance to antibodies elicited by natural SARS-CoV-2 infection and vaccination. METHODS: However, it remains unclear which mutations determine the resistance of SARS-CoV-2 Mu to antiviral sera. In addition, it is unclear how SARS-CoV-2 Mu infection induces antiviral immunity. RESULTS: In this study, we reveal that the 2 mutations in the SARS-CoV-2 Mu spike protein, YY144-145TSN and E484K, are responsible for the resistance to coronavirus disease 2019 convalescent sera during early 2020 and vaccine sera. CONCLUSIONS: It is notable that the convalescent sera of SARS-CoV-2 Mu-infected individuals are broadly antiviral against Mu as well as other SARS-CoV-2 variants of concern and interest.
Authors: Juan Hernandez-Ortiz; Andres Cardona; Karl Ciuoderis; Francisco Averhoff; Maria-Angelica Maya; Gavin Cloherty; Jorge E Osorio Journal: JAMA Netw Open Date: 2022-03-01
Authors: Edmilson F de Oliveira-Filho; Bladimiro Rincon-Orozco; Natalia Jones-Cifuentes; Brigitte Peña-López; Barbara Mühlemann; Christian Drosten; Andres Moreira-Soto; Jan Felix Drexler Journal: Emerg Infect Dis Date: 2022-07-13 Impact factor: 16.126